Jian-Pi-Yi-Shen, a Chinese herbal decoction, found to promote kidney health
(Natural News) Researchers at Guangzhou University of Chinese Medicine and The Hong Kong University of Science and Technology have found that Jian-Pi-Yi-Shen, a Chinese herbal decoction, can improve chronic kidney disease (CKD) associated with anemia. In the study, published in the journal BMC Complementary and Alternative Medicine, they looked at the effect of Jian-Pi-Yi-Shen on the expressions...
This article aims to establish the suitable hemoglobin in order to provide clinical guidance. METHODS: MEDLINE, EmBase, the Cochrane Library and other databases were searched with both MeSH terms and keywords to gather randomized controlled trials that assessed all-cause mortality, cardiovascular events, fistula thrombosis, infectious diseases and transfusion among dialysis-dependent patients using erythropoiesis-stimulating agents. The meta-analysis was accomplished via Revman 5.3 version. FINDINGS: Totally, nine eligible studies were included, with study subjects involving 3228 patients. There was a significantly...
CONCLUSIONS: Statin may have a small but potentially beneficial effect on serum hepcidin, which may lead to improvement of anemia control in CKD patients. PMID: 30741616 [PubMed - in process]
Vadadustat is a potential new treatment for anemia in chronic kidney disease -- but what do we know about its impacts in patients receiving hemodialysis?Nephrology Dialysis Transplantation
Conclusions: Enarodustat corrects and maintains Hb levels in anemic patients with CKD not on dialysis.Am J Nephrol 2019;49:165 –174
CONCLUSIONS: Enarodustat corrects and maintains Hb levels in anemic patients with CKD not on dialysis. PMID: 30699415 [PubMed - as supplied by publisher]
AbstractAnemia is a common complication of chronic kidney disease (CKD) in adult and pediatric patients. It has traditionally been treated with erythropoietin therapy and iron supplementation, with great success. With the discovery of the major transcription factor hypoxia inducible factor (HIF) for the erythropoietin gene in 1992, molecules were created that inhibit the HIF prolyl-hydroxylase enzyme. This new class of drug —called HIF stabilizers, or HIF prolyl-hydroxylase inhibitors—prevents the proteasomal degradation of HIF-α, thereby inducing upregulation of the erythropoietin gene. This new strategy...
ConclusionThese findings showed convincing evidences that DLBS6747 increases endogenous EPO production primarily via upregulation of its transcription factors, especially HIF1α, in human embryonic kidney HEK293 cells. This is the first molecular report that reveals the mechanism of action of natural-based erythropenia drug in different oxygen availability.Graphical abstract
Dr Thomas S. Huber (Gainesville, Fla). The authors have analyzed the impact of preoperative anemia on the perioperative outcomes of both open and endovascular repair for intact aneurysms using the Vascular Quality Initiative. They have reported that anemia is associated with increased 30-day mortality and adverse outcome for endovascular but not open repair in their multivariate analysis. They reported that the adverse outcomes associated with anemia were independent of chronic kidney disease and congestive heart failure.
ConclusionWith increasing pressure for cost containment in an era of bundled payment models, the very low rate of laboratory associated interventions suggest that routine postoperative laboratory tests is not justified. Obtaining laboratory after primary, unilateral TKA should be driven by patients’ risk factors.
Conclusions: Higher MCV was associated with higher all-cause, cardiovascular, and infectious mortality in HD patients. Further investigation is necessary to understand the underlying nature of the observed association.Nephron